Detalhe da pesquisa
1.
Tetherin antagonism by SARS-CoV-2 ORF3a and spike protein enhances virus release.
EMBO Rep
; 24(12): e57224, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37818801
2.
Inhibition of the Lectin Pathway of Complement Activation Reduces Acute Respiratory Distress Syndrome Severity in a Mouse Model of SARS-CoV-2 Infection.
J Infect Dis
; 229(3): 680-690, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37878754
3.
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
J Virol
; 95(15): e0020321, 2021 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963055
4.
Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.
J Allergy Clin Immunol Glob
; 2(2): 100091, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37038555
5.
Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.
Front Immunol
; 14: 1118523, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36911730
6.
The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity.
iScience
; 26(11): 108080, 2023 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37860693
7.
Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.
Vaccines (Basel)
; 10(9)2022 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36146598
8.
Tetherin antagonism by SARS-CoV-2 enhances virus release: multiple mechanisms including ORF3a-mediated defective retrograde traffic.
bioRxiv
; 2022 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33442692
9.
Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds.
Front Immunol
; 13: 773982, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35330908
10.
SARS-CoV-2 nucleocapsid protein adheres to replication organelles before viral assembly at the Golgi/ERGIC and lysosome-mediated egress.
Sci Adv
; 8(1): eabl4895, 2022 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995113
11.
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
JCI Insight
; 7(13)2022 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608920
12.
Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines.
Vaccines (Basel)
; 9(2)2021 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33525543
13.
Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display.
Sci Rep
; 11(1): 3126, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33542302
14.
AutoPlate: Rapid Dose-Response Curve Analysis for Biological Assays.
Front Immunol
; 12: 681636, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35222351
15.
Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.
Vaccines (Basel)
; 9(7)2021 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34358157
16.
Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
Front Immunol
; 12: 748291, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34867975
17.
Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin.
Antibodies (Basel)
; 8(1)2019 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31544820
18.
Editorial: Novel approaches to prevention, diagnosis, and treatment of bacterial and viral infections of clinical relevance.
Front Microbiol
; 14: 1192435, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125178
19.
A naturally protective epitope of limited variability as an influenza vaccine target.
Nat Commun
; 9(1): 3859, 2018 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30242149